HRP20020428B1 - Bicyclic amino acids as pharmaceutical agents - Google Patents

Bicyclic amino acids as pharmaceutical agents

Info

Publication number
HRP20020428B1
HRP20020428B1 HR20020428A HRP20020428A HRP20020428B1 HR P20020428 B1 HRP20020428 B1 HR P20020428B1 HR 20020428 A HR20020428 A HR 20020428A HR P20020428 A HRP20020428 A HR P20020428A HR P20020428 B1 HRP20020428 B1 HR P20020428B1
Authority
HR
Croatia
Prior art keywords
amino acids
pharmaceutical agents
bicyclic amino
bicyclic
hept
Prior art date
Application number
HR20020428A
Other languages
English (en)
Croatian (hr)
Inventor
Clive Blakemore David
Receveur Jean-Marie
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of HRP20020428A2 publication Critical patent/HRP20020428A2/xx
Publication of HRP20020428B1 publication Critical patent/HRP20020428B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
HR20020428A 1999-10-20 2002-05-15 Bicyclic amino acids as pharmaceutical agents HRP20020428B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20
PCT/US2000/028687 WO2001028978A1 (fr) 1999-10-20 2000-10-17 Acides amines bicycliques utilises comme agents pharmaceutiques

Publications (2)

Publication Number Publication Date
HRP20020428A2 HRP20020428A2 (en) 2005-02-28
HRP20020428B1 true HRP20020428B1 (en) 2006-02-28

Family

ID=22578159

Family Applications (2)

Application Number Title Priority Date Filing Date
HR20020428A HRP20020428B1 (en) 1999-10-20 2002-05-15 Bicyclic amino acids as pharmaceutical agents
HRP20040709 HRP20040709A2 (en) 1999-10-20 2004-08-04 Bicyclic amino acids as pharmaceutical agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20040709 HRP20040709A2 (en) 1999-10-20 2004-08-04 Bicyclic amino acids as pharmaceutical agents

Country Status (50)

Country Link
US (2) US6689906B1 (fr)
EP (2) EP1506955B1 (fr)
JP (2) JP3632191B2 (fr)
KR (2) KR100566462B1 (fr)
CN (1) CN1165518C (fr)
AP (2) AP2002002517A0 (fr)
AR (2) AR026087A1 (fr)
AT (2) ATE358116T1 (fr)
AU (2) AU778871B2 (fr)
BG (2) BG108860A (fr)
BR (1) BR0014972B1 (fr)
CA (1) CA2386297C (fr)
CO (1) CO5280060A1 (fr)
CR (1) CR6620A (fr)
CU (1) CU23112A3 (fr)
CZ (1) CZ295960B6 (fr)
DE (2) DE60019628T2 (fr)
DO (1) DOP2000000083A (fr)
DZ (1) DZ3197A1 (fr)
EA (1) EA005206B1 (fr)
EC (1) ECSP045393A (fr)
EE (1) EE200200211A (fr)
ES (2) ES2282785T3 (fr)
GE (1) GEP20043297B (fr)
GT (2) GT200000183AA (fr)
HK (1) HK1049826B (fr)
HN (1) HN2000000224A (fr)
HR (2) HRP20020428B1 (fr)
HU (1) HUP0203325A3 (fr)
IL (3) IL149143A0 (fr)
IS (2) IS6348A (fr)
MA (1) MA26842A1 (fr)
MX (1) MXPA02003229A (fr)
MY (1) MY127678A (fr)
NO (2) NO20021780L (fr)
NZ (1) NZ517961A (fr)
OA (1) OA12070A (fr)
PA (1) PA8505201A1 (fr)
PE (1) PE20010740A1 (fr)
PL (1) PL354607A1 (fr)
PT (1) PT1226110E (fr)
SI (1) SI1226110T1 (fr)
SK (1) SK5232002A3 (fr)
SV (1) SV2001000188A (fr)
TR (2) TR200201094T2 (fr)
TW (2) TW200505824A (fr)
UA (1) UA72931C2 (fr)
WO (1) WO2001028978A1 (fr)
YU (2) YU73004A (fr)
ZA (1) ZA200202543B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
IL152770A0 (en) * 2000-06-26 2003-06-24 Warner Lambert Co Gabapentin analogues for sleep disorders
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (fr) * 2001-01-26 2002-07-31 Warner-Lambert Company Utilisation d'acides aminés bicycliques pour la prevention et le traitement des douleurs viscérales ainsi que des maladies gastrointestinales
SK12822003A3 (sk) 2001-04-19 2004-04-06 Warner - Lambert Company Llc Fúzne bicyklické alebo tricyklické aminokyseliny
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ES2380287T3 (es) * 2001-06-11 2012-05-10 Xenoport, Inc. Profármacos de análogos de GABA, composiciones y sus usos
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2474000A1 (fr) * 2002-01-31 2003-08-07 Warner-Lambert Company Llc Ligands alpha 2 delta dans le traitement des acouphenes
RU2286151C2 (ru) * 2002-02-22 2006-10-27 Уорнер-Ламберт Компани Ллс Комбинации альфа-2-дельта-лиганда с селективным ингибитором циклооксигеназы-2
CN1678298A (zh) * 2002-06-27 2005-10-05 沃纳-兰伯特公司 α2δ配体如加巴喷丁或普瑞巴林用于治疗注意力缺陷的过度反应症的用途
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
BR0313432A (pt) * 2002-08-15 2005-07-12 Pfizer Uso terapêutico de aminoácidos bicìclicos ou tricìclicos fundidos
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (fr) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Utilisations pharmaceutiques de ligands alpha2delta
EP1572173B1 (fr) 2002-12-13 2010-04-28 Warner-Lambert Company LLC Ligand alpha-2-delta pour traiter des symptomes des voies urinaires inferieures
CA2505788A1 (fr) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Derives de pregabalin pour le traitement de la fibromyalgie et d'autres troubles
CA2537402C (fr) 2003-09-12 2009-05-05 Pfizer Inc. Associations comprenant des ligands alpha-2-delta et des inhibiteurs du recaptage de la serotonine et de la noradrenaline
WO2006092692A1 (fr) * 2005-03-01 2006-09-08 Pfizer Limited Utilisation d'associations d’inhibiteurs de pde7 et de ligands alpha-2-delta pour le traitement de la douleur neuropathique
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
EA017171B1 (ru) 2006-12-22 2012-10-30 Рекордати Айерленд Лимитед КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП)
PT2192109E (pt) 2007-09-28 2013-12-09 Daiichi Sankyo Co Ltd Derivado de -aminoácido bicíclico
CN102356061B (zh) 2009-03-26 2014-02-19 第一三共株式会社 用于制备二环γ-氨基酸衍生物的方法
BR112013031365B1 (pt) 2011-06-08 2021-09-28 Daiichi Sankyo Company, Limited Método para produzir um composto
ES2659162T3 (es) 2011-06-08 2018-03-14 Daiichi Sankyo Company, Limited Procedimiento de producción de compuesto bicíclico a través de una sal de iminio
BR112014014432B1 (pt) 2011-12-15 2022-03-29 Daiichi Sankyo Company, Limited Método para produzir um composto
CN104245951B (zh) 2012-04-10 2018-08-24 第一三共株式会社 使用酶对二环化合物光学拆分的方法
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
WO2018166855A1 (fr) 2017-03-16 2018-09-20 Basf Se Dihydroisoxazoles à substitution hétérobicyclique
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
CN1138755C (zh) 1997-10-27 2004-02-18 沃尼尔·朗伯公司 作为药物的环状氨基酸及其衍生物

Also Published As

Publication number Publication date
CN1165518C (zh) 2004-09-08
GT200000183AA (es) 2005-06-17
IS6348A (is) 2002-04-17
JP2005036009A (ja) 2005-02-10
MA26842A1 (fr) 2004-12-20
UA72931C2 (uk) 2005-05-16
IL149143A0 (en) 2002-11-10
TWI225855B (en) 2005-01-01
CR6620A (es) 2004-02-02
DE60019628T2 (de) 2006-01-19
YU29302A (sh) 2005-06-10
HK1049826A1 (en) 2003-05-30
BG106719A (bg) 2003-02-28
EA200200293A1 (ru) 2002-10-31
EP1506955B1 (fr) 2007-03-28
KR100593349B1 (ko) 2006-06-26
HK1049826B (zh) 2005-02-25
BR0014972A (pt) 2002-07-16
NO20043663L (no) 2002-04-16
ES2237464T3 (es) 2005-08-01
DZ3197A1 (fr) 2001-04-26
KR100566462B1 (ko) 2006-03-31
CA2386297A1 (fr) 2001-04-26
JP3744928B2 (ja) 2006-02-15
PL354607A1 (en) 2004-01-26
ZA200202543B (en) 2003-09-23
HN2000000224A (es) 2001-04-11
TR200201094T2 (tr) 2002-09-23
DOP2000000083A (es) 2002-03-30
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
CO5280060A1 (es) 2003-05-30
CN1382118A (zh) 2002-11-27
EP1226110B1 (fr) 2005-04-20
HRP20020428A2 (en) 2005-02-28
PE20010740A1 (es) 2001-07-27
MY127678A (en) 2006-12-29
US6835751B2 (en) 2004-12-28
CZ20021310A3 (cs) 2003-05-14
ATE358116T1 (de) 2007-04-15
DE60034157T2 (de) 2007-12-13
HUP0203325A2 (hu) 2003-02-28
JP2003512348A (ja) 2003-04-02
MXPA02003229A (es) 2002-09-30
AU2005201268A1 (en) 2005-04-21
IL149143A (en) 2007-02-11
HRP20040709A2 (en) 2004-12-31
SK5232002A3 (en) 2003-07-01
AU1092001A (en) 2001-04-30
BG108860A (en) 2006-03-31
EP1226110A1 (fr) 2002-07-31
EA005206B1 (ru) 2004-12-30
US6689906B1 (en) 2004-02-10
NO20021780D0 (no) 2002-04-16
PT1226110E (pt) 2005-07-29
EE200200211A (et) 2003-06-16
HUP0203325A3 (en) 2003-12-29
DE60034157D1 (de) 2007-05-10
PA8505201A1 (es) 2002-08-29
WO2001028978A1 (fr) 2001-04-26
TW200505824A (en) 2005-02-16
DE60019628D1 (de) 2005-05-25
AP2004003186A0 (en) 2004-12-31
KR20060013701A (ko) 2006-02-13
NO20021780L (no) 2002-04-16
SV2001000188A (es) 2001-09-07
AR026087A1 (es) 2002-12-26
YU73004A (sh) 2005-11-28
IL164060A0 (en) 2005-12-18
IS7497A (is) 2004-10-08
AU778871B2 (en) 2004-12-23
SI1226110T1 (en) 2005-08-31
US20040152779A1 (en) 2004-08-05
AR045456A2 (es) 2005-10-26
ATE293590T1 (de) 2005-05-15
ES2282785T3 (es) 2007-10-16
AP2002002517A0 (en) 2002-06-30
KR20020040900A (ko) 2002-05-30
BR0014972B1 (pt) 2011-09-06
CU23112A3 (es) 2006-02-27
EP1506955A1 (fr) 2005-02-16
CA2386297C (fr) 2010-02-09
OA12070A (en) 2003-11-10
ECSP045393A (es) 2004-10-23
NZ517961A (en) 2002-12-20
TR200500221T2 (tr) 2005-03-21
CZ295960B6 (cs) 2005-12-14
JP3632191B2 (ja) 2005-03-23

Similar Documents

Publication Publication Date Title
HRP20020428B1 (en) Bicyclic amino acids as pharmaceutical agents
EP1040823A3 (fr) Formulations de mousse stabiles
IS2863B (is) Arípíprazóllausn til gjafar um munn
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
ATE297203T1 (de) Antithrombotische mitteln
BG104631A (en) Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
DE69705300D1 (de) Cyclopropylalkansäurederivate
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
HUP0203130A2 (hu) Hexahidrofuro[2,3-b]furán-3-il-N-{3-(1,3-benzodioxol-5-il-szulfonil)-(izobutil)-amino-1-benzil-2-(hidroxi-propil)}-karbamát mint retrovírus-proteáz-gátló
YU52000A (sh) Jedinjenja meta-azaciklične amino benzojeve kiseline i njihovi derivati, koji su antagonisti integrina
WO2001096307A3 (fr) Acides alcanoiques cycloalkyles comme antagonistes d'integrines
TR200201168T2 (tr) CGRP-Antagonistleri-yeni siklopropanlar içeren ilaçlar ve üretim yöntemleri.
AU7270798A (en) Antithrombotic agents
AU4770400A (en) Fused polycyclic amino acids as pharmaceutical agents
PL377478A1 (pl) Cykloalkenowe kwasy dikarboksylowe jako środki przeciwzapalne, immunomodulujące oraz antyproliferacyjne
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
WO2004048381A3 (fr) Nouveaux composes de pyrazoloazepine utilises en tant qu'agents pharmaceutiques
EP1027051A4 (fr) Agents antithrombotiques
YU87501A (sh) Farmaceutski kompleksi
ATE307809T1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
DE60029979D1 (de) LIPOSOMZUSAMMENSETZUNG VON 6,9-BIS-i(2-AMINOETHYL)-AMINOöBENZOiGöISOQUINOLIN-5,10-DIONE-DIMALEAT
AU1434201A (en) Antithrombotic agents
NO20014889L (no) Fremgangsmåte for fremstilling av medisinske midler
DE69824410D1 (en) Antithrombosemittel
HUP9902307A2 (hu) Új, áthidalt gyűrűs aminosavak, előállításuk és intermedierjeik

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20061002

Year of fee payment: 7

PBON Lapse due to non-payment of renewal fee

Effective date: 20071018